Plagerine Tablets (Clopidogrel ).

• Composition :
  Each capsule contains Clopidogrel 75mg.
• Indications :
  For treatment of atherosclerosis events (myocardial infarction, stroke & vascular death), acute coronary syndrome.
• Pharmacodynamics :
  Clopidogrel is a prodrug and is metabolized an active thiol metabolite. The active metabolite selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein GP IIb/IIIa complex, thereby inhibiting platelet aggregation.
• Dosage and administration :
  Once daily orally.
• Contraindications :
  Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage and hypersensitivity to clopidogrel or any component of the product.
• Precautions and warnings :
  Plagerine should be discontinued 5 days prior to surgery, Thrombotic thrombocytopenic purpura (TTP) including fatal cases have been reported. Premature discontinuation increases risk of cardiovascular events.
• Use in pregnancy, lactation & pediatrics :
  Pregnancy Category B, no adequate and well-controlled studies in pregnant women. Discontinue the drug during nursing. Safety and effectiveness in the pediatric population have not been established.
• Drug interactions :
  Concomitant administration of warfarin and NSAID with plagerine should be undertaken with caution, Plagerine potentiated the effect of aspirin and avoid concomitant use with drugs that are strong or moderate CYP2C19 inhibitors (e.g., omeprazole).
• Adverse reactions :
  Bleeding, hepatitis, Dizziness, hypersensitivity reactions, Upper respiratory tract infection and back pain is the most commonly reported adverse reaction.
• Therapy Area :
  Anti-Platelets